Registry following adults with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
Tracks safety of biologic or targeted drugs in adults with joint inflammation during routine care.
Plain-language title generated from the registry record
Registry title: Korean College of Rheumatology Biologics and Targeted Therapy Registry
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Seoul Metropolitan Government Seoul National University Boramae Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Seoul National University Hospital
- Trial code
- NCT01965132
- Record updated
- 26 April 2024
- Original description
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.Read full original descriptionShow less
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.
Inclusion: Patients diagnosed with RA, AS or PsA; RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s); AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD; Patients who provide a written consent of participating in this registry (data collection and review).
Exclusion: RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening.